431 related articles for article (PubMed ID: 17785763)
1. Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck.
Bernier J; Bonner J; Vermorken JB; Bensadoun RJ; Dummer R; Giralt J; Kornek G; Hartley A; Mesia R; Robert C; Segaert S; Ang KK
Ann Oncol; 2008 Jan; 19(1):142-9. PubMed ID: 17785763
[TBL] [Abstract][Full Text] [Related]
2. Management of radiation dermatitis in patients receiving cetuximab and radiotherapy for locally advanced squamous cell carcinoma of the head and neck: proposals for a revised grading system and consensus management guidelines.
Bernier J; Russi EG; Homey B; Merlano MC; Mesía R; Peyrade F; Budach W
Ann Oncol; 2011 Oct; 22(10):2191-200. PubMed ID: 21606209
[TBL] [Abstract][Full Text] [Related]
3. Management of dermatitis in patients with locally advanced squamous cell carcinoma of the head and neck receiving cetuximab and radiotherapy.
Cabezón-Gutiérrez L; Khosravi-Shahi P; Escobar-Álvarez Y
Oral Oncol; 2012 Apr; 48(4):293-7. PubMed ID: 22137799
[TBL] [Abstract][Full Text] [Related]
4. Early tumor progression associated with enhanced EGFR signaling with bortezomib, cetuximab, and radiotherapy for head and neck cancer.
Argiris A; Duffy AG; Kummar S; Simone NL; Arai Y; Kim SW; Rudy SF; Kannabiran VR; Yang X; Jang M; Chen Z; Suksta N; Cooley-Zgela T; Ramanand SG; Ahsan A; Nyati MK; Wright JJ; Van Waes C
Clin Cancer Res; 2011 Sep; 17(17):5755-64. PubMed ID: 21750205
[TBL] [Abstract][Full Text] [Related]
5. Incidence of skin toxicity in squamous cell carcinoma of the head and neck treated with radiotherapy and cetuximab: A systematic review.
Bonomo P; Loi M; Desideri I; Olmetto E; Delli Paoli C; Terziani F; Greto D; Mangoni M; Scoccianti S; Simontacchi G; Francolini G; Meattini I; Caini S; Livi L
Crit Rev Oncol Hematol; 2017 Dec; 120():98-110. PubMed ID: 29198343
[TBL] [Abstract][Full Text] [Related]
6. Radiotherapy related skin toxicity (RAREST-01): Mepitel® film versus standard care in patients with locally advanced head-and-neck cancer.
Narvaez C; Doemer C; Idel C; Setter C; Olbrich D; Ujmajuridze Z; Carl JH; Rades D
BMC Cancer; 2018 Feb; 18(1):197. PubMed ID: 29454311
[TBL] [Abstract][Full Text] [Related]
7. The role of cetuximab in the treatment of squamous cell cancer of the head and neck.
Burtness B
Expert Opin Biol Ther; 2005 Aug; 5(8):1085-93. PubMed ID: 16050785
[TBL] [Abstract][Full Text] [Related]
8. [Cutaneous side effects of EGFR inhibitors--appearance and management].
Wollenberg A; Kroth J; Hauschild A; Dirschka T
Dtsch Med Wochenschr; 2010 Jan; 135(4):149-54. PubMed ID: 20101558
[TBL] [Abstract][Full Text] [Related]
9. Differentiation of irradiation and cetuximab induced skin reactions in patients with locally advanced head and neck cancer undergoing radioimmunotherapy: the HICARE protocol (head and neck cancer: immunochemo and radiotherapy with erbitux) - a multicenter phase IV trial.
Habl G; Potthoff K; Haefner MF; Abdollahi A; Hassel JC; Boller E; Indorf M; Debus J
BMC Cancer; 2013 Jul; 13():345. PubMed ID: 23855804
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001).
Prawira A; Brana-Garcia I; Spreafico A; Hope A; Waldron J; Razak AR; Chen EX; Jang R; O'Sullivan B; Giuliani M; Bayley A; Cho J; Wang L; Perez-Ordonez B; Weinreb I; Siu LL; Hansen AR
Invest New Drugs; 2016 Oct; 34(5):575-83. PubMed ID: 27289242
[TBL] [Abstract][Full Text] [Related]
11. Cetuximab, paclitaxel, carboplatin, and radiation for head and neck cancer: a toxicity analysis.
Birnbaum A; Dipetrillo T; Rathore R; Anderson E; Wanebo H; Puthwala Y; Joyce D; Safran H; Henderson D; Kennedy T; Ready N; Sio TT
Am J Clin Oncol; 2010 Apr; 33(2):144-7. PubMed ID: 19786848
[TBL] [Abstract][Full Text] [Related]
12. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.
Bonner JA; Harari PM; Giralt J; Cohen RB; Jones CU; Sur RK; Raben D; Baselga J; Spencer SA; Zhu J; Youssoufian H; Rowinsky EK; Ang KK
Lancet Oncol; 2010 Jan; 11(1):21-8. PubMed ID: 19897418
[TBL] [Abstract][Full Text] [Related]
13. Adverse skin reactions during treatment with cetuximab plus radiotherapy: Multidisciplinary approach to minimize radio-chemotherapy interruption.
Ricci F; Paradisi A; Silveri SL; Sampogna F; Miccichè F; Bonomo PL; DiNapoli N; Valentini V; Capizzi R; Guerriero C
J Dermatolog Treat; 2015 Apr; 26(2):183-7. PubMed ID: 24852820
[TBL] [Abstract][Full Text] [Related]
14. The efficacy of combined treatment with cetuximab (erbitux) and radiation therapy in patients with head and neck cancer.
Koukourakis G; Kouloulias V; Koukourakis M; Kouvaris J; Zacharias G; Gouliamos A
J BUON; 2009; 14(1):19-25. PubMed ID: 19373942
[TBL] [Abstract][Full Text] [Related]
15. Grading system and management guidelines for dermatitis induced by head and neck radiotherapy plus cetuximab: clinical validation required.
Langendijk JA; Oosting SF
Ann Oncol; 2011 Oct; 22(10):2157-9. PubMed ID: 21878428
[No Abstract] [Full Text] [Related]
16. Overview of Current Treatment Options and Investigational Targeted Therapies for Locally Advanced Squamous Cell Carcinoma of the Head and Neck.
Zibelman M; Mehra R
Am J Clin Oncol; 2016 Aug; 39(4):396-406. PubMed ID: 26967327
[TBL] [Abstract][Full Text] [Related]
17. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.
Bonner JA; Harari PM; Giralt J; Azarnia N; Shin DM; Cohen RB; Jones CU; Sur R; Raben D; Jassem J; Ove R; Kies MS; Baselga J; Youssoufian H; Amellal N; Rowinsky EK; Ang KK
N Engl J Med; 2006 Feb; 354(6):567-78. PubMed ID: 16467544
[TBL] [Abstract][Full Text] [Related]
18. Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion.
Potthoff K; Hofheinz R; Hassel JC; Volkenandt M; Lordick F; Hartmann JT; Karthaus M; Riess H; Lipp HP; Hauschild A; Trarbach T; Wollenberg A
Ann Oncol; 2011 Mar; 22(3):524-535. PubMed ID: 20709812
[TBL] [Abstract][Full Text] [Related]
19. Cetuximab: a review of its use in squamous cell carcinoma of the head and neck.
Frampton JE
Drugs; 2010 Oct; 70(15):1987-2010. PubMed ID: 20883055
[TBL] [Abstract][Full Text] [Related]
20. A retrospective, multicenter study of the tolerance of induction chemotherapy with docetaxel, Cisplatin, and 5-Fluorouracil followed by radiotherapy with concomitant cetuximab in 46 cases of squamous cell carcinoma of the head and neck.
Buiret G; Combe C; Favrel V; Pommier P; Martin L; Ecochard R; Fayette J; Tartas S; Ramade A; Céruse P
Int J Radiat Oncol Biol Phys; 2010 Jun; 77(2):430-7. PubMed ID: 19775831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]